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ABSTRACT
Objective: Endogenous production of glutamine may be reduced during critical illness. The shortage of glutamine is reflected as a decrease in plasma 
concentration, which is a prognostic factor for outcome in sepsis. Therefore, we have studied the effect of enteral or parenteral glutamine therapy on 
biochemical parameters and the hospital stay of critically ill patients.
Methods: A total of 66 critically ill patients aged 18-70 years, admitted to central and medical intensive care unit of a tertiary care hospital were 
randomly divided into three equal groups; 22 in each group: Group 1 (control group) received no glutamine, Group 2 received oral glutamine 
0.5 g/kg/d for 5 days, and Group 3 received parenteral glutamine 0.5 g/kg/d by intravenous infusion for 5 days. All patients received glutamine-free 
tube feed throughout the study period. Total leukocyte count (TLC), total lymphocyte count, total protein and serum albumin, serum lactate, and 
sequential organ failure assessment (SOFA) score were recorded on each day for 7 days and were compared.
Results: Decrease in the TLC and increase in lymphocyte count was most evident in Group 3 compared to Groups 2 and 1 which was statistically 
significant. Decrease in serum lactate and increase in serum protein and albumin was maximum in Group 3 compared to Groups 1 and 2 which was 
statistically significant. The mean duration of hospital stay of Group 3 was the least followed by Groups 2 and 1 which was statistically not significant. 
There was an improvement in SOFA score in all the three groups.
Conclusion: Parenteral glutamine in a dose of 0.5 g/kg/d was more potent than oral glutamine in improving the biochemical parameters. The duration 
of hospital stay was similar in all the groups after treatment.
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INTRODUCTION
Glutamine is a nonessential amino acid that can become conditionally 
essential under catabolic states such as critical illness and burns [1]. It 
is synthesized by the enzyme glutamine synthetase from glutamate and 
ammonia predominantly by muscle but also in small amounts by the 
lung and brain. It plays a central role as a fuel source for enterocytes, 
lymphocytes, and other rapidly dividing cells of the immune system [2]. 
Although glutamine and glutamate comprises 10-20% of dietary 
protein, no net absorption occurs as these amino acids undergo 
significant metabolism in the enterocyte, serving as a major respiratory 
fuel [3]. As dietary glutamine supplies are exhausted, the enterocytes 
begin to rely on circulating glutamine. Systemic glutamine availability 
is determined by the balance of endogenous glutamine production 
(mainly in muscular tissue) and its use by glutamine consuming 
organs (gut, kidney, liver, and the immune system) [4]. Several studies 
have shown that in catabolic patients, the endogenous production of 
muscular glutamine is increased while the plasma levels or glutamine 
are decreased, indicating elevated glutamine needs. Studies have 
shown that low plasma glutamine values on admission are related to 
increased mortality [5]. These findings are the rationale for the use of 
glutamine supplementation in the intensive care unit (ICU) patients to 
meet the demand for improvement in protein synthesis, modulation of 
the immune system, reduction of oxidative stress, and preservation of 
the gut barrier. Glutamine is safe up to 40 g/day with either enteral or 
parenteral route. Still it is not clear which route is better [6,7]. Some 
studies are there stating parenteral nutrition may be better than enteral 
nutrition in terms of clinical outcome in patients getting parenteral 
nutrition. However, in patients getting enteral nutrition, studies differ 
whether enteral or parenteral route to be preferred for glutamine 
administration [8-10]. The objective of this study was to evaluate 
the effect of parenteral glutamine and oral glutamine in critically ill 
patients. The primary objective of our study was to measure changes 
in the biochemical parameters such as total leukocyte count (TLC), 
lymphocyte count, serum protein and serum albumin and serum lactate 
levels. The secondary objective was to measure the effect on duration of 
hospital stay and mortality.
METHODS
This was a prospective randomized, single-blinded, placebo controlled 
study done at central and medical ICU, SCB Medical College, Cuttack, 
between September 2014 and October 2016 after due permission from 
the hospital ethical committee. This study was done on 66 patients of age 
18-70 years who were critically ill and accepting standard enteral feeds. 
Reason of ICU admission, i.e., medical reasons (respiratory failure, CVA), 
elective surgery (major abdominal surgery, major thoracic surgery, 
and spine surgery), or emergency surgeries (perforation peritonitis, 
polytrauma). Patients with APACHE II score from 10 to 20 and expected 
stay in ICU>7 days were included in this study. Patients having renal 
failure, pregnancy, hepatic failure, patients receiving cytotoxic drugs, 
steroids and radiation therapy, unable to tolerate enteral feed within 
72 hrs of admission and patients with gastrointestinal bleeding or 
intestinal obstruction were excluded from the study. The patients were 
divided into three groups of 22 each. Randomization was done using 
the random number table, and concealment was done by the sealed 
envelope technique. Demographic variables were age, gender, and 
weight. APACHE II score at the time of admission, baseline hematological 
counts, serum electrolytes, serum protein, albumin, bilirubin, lactate, 
serum urea, and creatinine levels were recorded. On admission to 
the ICU, after adequate resuscitation, confirmation of hemodynamic 
stability, gut integrity and acceptance of test feed, enteral nutrition 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i8.18984
Research Article
236
Asian J Pharm Clin Res, Vol 10, Issue 8, 2017, 235-239
 Das et al. 
was started via the nasogastric tube (in semi-recumbent position) 
preferably within 24 hrs of ICU admission. All the patients received the 
standard enteral feed in the ICU 30 kcal/kg/day including carbohydrate 
(70%), fat (30%), and protein 1.5 g/kg/day in accordance with the 
enteral feeding guidelines. The study groups received the following 
supplementation: Group 1-(Control): Received standard enteral feed 
along with 100 ml normal saline infusion. Group 2-(Enteral glutamine): 
Received standard enteral feed along with 0.5 g/kg/day of glutamine 
along with 100 ml of normal saline infusion. Group 3-(Parenteral 
glutamine): Received standard enteral feed along with 0.5 g/kg/day of 
IV glutamine as an infusion. The glutamine supplementation was given 
for 7 days after which the patients continued to receive the standard 
enteral feed. The sedation, acid suppression, antibiotics, fluid therapy, 
insulin therapy, and weaning were done as per the ICU protocol in all 
the patients. The TLC, lymphocyte count, total platelet count, serum 
protein, serum albumin, serum urea, serum creatinine, serum bilirubin, 
serum lactate, and blood glucose were sent every morning at around 
8 am. Sequential organ failure assessment (SOFA) score was assessed 
every day from day 1 to day 7.
The primary outcomes studied were the effect of glutamine 
supplementation on serum lactate, TLC, total serum lymphocyte count, 
serum protein and albumin and SOFA score. The secondary outcomes 
studied were the length of stay (LOS) in ICU, days of mechanical 
ventilation and mortality in ICU. The change in serum lactate level was 
used as primary endpoints. The analysis determined that 25 patients 
per group would provide 80% power to determine the minimal 
detectable difference of 0.5 meq/l of serum lactate between glutamine-
supplemented parenteral nutrition and standard nutrition. Statistical 
analysis was performed suing SPSS 20 software. The values were 
described as mean±standard deviation if normally distributed and 
as median and interquartile range if the distribution is skewed. Age, 
weight, and APACHE II score were analyzed by ANOVA. The discrete 
variables, i.e., sex and mortality were analyzed using Chi-square or 
Fischer’s exact test. The biochemical and clinical outcome parameters 
were analyzed by Kruskal–Wallis test. Paired analysis was performed 
by Mann–Whitney U-test between groups. Friedman test was used to 
analyze changes within a group. p<0.05 was considered significant. 
p<0.001 was considered as statistically highly significant.
RESULTS
There was no statistical difference with respect to age, gender, body 
mass index, and APACHE I score among three groups.
The mean APACHE II score in the control group was 14.45±4.22, enteral 
group was 13.68±2.8 and parenteral group was 14.2±4.16, and there 
was no statistically significant difference among the three. There was 
no statistically significant difference regarding no of days of mechanical 
ventilation, serum bilirubin, serum lactate, serum creatinine, and 
blood glucose among the three groups. Furthermore, SOFA score was 
comparable within three groups (Table 1).
The improvement in laboratory parameters within each group was 
analyzed by comparing the median values of each parameter on days 
1, 4 and 7 by Friedman test. In Group 1, there was no significant change 
in serum lactate level. There was a significant improvement in SOFA 
score in Group 1 between days 1 and 7, other values being statistically 
insignificant (Table 2).
In Group 2, the lymphocyte count increased appreciably from day 1 
to day 7 but did not attain statistical significance. Serum albumin also 
increased markedly in Group 2 but not statistically significant. There was 
no significant change in serum lactate level, but there was a statistically 
significant improvement in SOFA score within the group in 7 days (Table 3).
In Group 3, there was statistically significant improvement in serum 
lactate, leukocyte count, lymphocyte count, and serum albumin and 
protein from day 1 to day 7. Improvement in SOFA score from day 1 to 
day 7 was statistically highly significant (Table 4).
The mortality in the ICU between the groups was analyzed suing 
Fischer’s exact test. The mortality rate among the three groups was not 
statistically significant. The mortality rate in the parenteral group was 
lesser when compared to the control or enteral group. However, this did 
not attain any statistical significance (Fig. 1).
The LOS in ICU and duration of mechanical ventilation was analyzed 
using Kruskal–Wallis test. The median LOS was 19.5 days in Group 1, 
17 days in Group 2, and 19 days in Group 3 and no statistical significance 
was observed among the groups (Fig. 2).
DISCUSSION
Nutrition has an important role in all ICU patients to combat the 
increased demand, maintain the basal function as well as to increase 
the immunological response. Enteral route is preferred due to its 
efficacy, safety, beneficial effect on gut function, and reduced side effects 
as compared to the parenteral route. It should be started within 24 hrs 
of ICU admission in patients who can tolerate oral feeding. Glutamine 
as an immune nutrient is recommended mainly in classes of patients 
such as burns and trauma. The benefit is however subjective depending 
on the route, dose, severity of illness, and other comorbidities. Over 
the years, many studies examining glutamine in ICU patients have 
presented controversial results. Recently, concluded redox study and 
Signet study has questioned the safety and efficacy of glutamine in 
critically ill patients. However, several published meta-analyses have 
initially showed a significant reduction in mortality and infectious 
morbidity. It is not easy to obtain a clear answer to the above-quoted 
question, as the critically ill population is a heterogeneous one. Studies 
often mix patients with different pathologies and prognosis, as well 
as include distinct routes of administration and the use of different 
doses than those recommended by the guidelines, thus giving mixed 
results, especially when compared to a metanalysis [11,12]. Hence, we 
studied the effect of enteral and parenteral glutamine supplementation 
in critically ill patients from a mixed medical and surgical ICU. The 
optimal dose of glutamine by enteral route is still unknown, but studies 
Fig. 1: Distribution of mortality among different groups
Fig. 2: Comparison of length of stay in intensive care unit and days 
of mechanical ventilation
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have safely used up to 0.5 g/kg/day [13]. Up to 40 g/day of L-glutamine 
is safe by combined enteral and parenteral route [14]. Heyland et al. 
recommended that at least 6 days of parenteral therapy with glutamine 
in therapeutic dose was required to derive maximum benefit [15]. So in 
our study, we used a dose of 0.5 g/kg/day for a duration of 7 days. Our 
study resembles the pilot study conducted by Luo et al. with respect 
to the setting and dosage of glutamine [16]. Day 1 SOFA score is an 
indicator of the severity of illness. In our study, the day 1 SOFA score 
median values were same in the three groups. The decrease in SOFA 
score was statistically significant in the three groups. However, the 
decrease in SOFA score from day 1 to day 7 was more in Group 3 as 
compared to 1 and 2. The median SOFA score decreased from 6 to 3.5 
in Group 1, 6 to 2.5 in Group 2, and 6 to 2 in Group 3. This indicates 
an appreciable improvement in disease states in Groups 2 and 3. 
Our study reflected an increased improvement in SOFA score in the 
parenteral group than in the entire group which is similar to study by 
Ferreira et al. [17]. This may be due to the delay in onset of action in 
the enteral glutamine group which may be due to impaired absorption 
in the intestinal villi, presence of immature villi, decreased blood flow 
in the gut, larger utilization by the enterocytes or metabolism by the 
splanchnic organs. The bioavailability of parenteral glutamine is 100%. 
This is consistent with the result of Beale et al. [18].
There was no significant change among the three groups with respect 
to the total leucocytes count, but the change was significant for total 
lymphocyte count on days 4 and 7. There was an improvement in 
lymphocyte count in both Groups 2 and 3 but reached significant levels 
only Group 3. This is consistent with the result of Fuentes-Orozco et al. 
who did not observe any different in the total leukocytes count [19]. 
In our study, there was a significant increase in albumin levels in 
Group 3 although the Group 2 also showed some improvement in 
serum albumin. These results correlate well with the study of Fuentes-
Orozco et al. who found an increase in protein and albumin counts 
in the glutamine-supplemented groups [19]. Ockenga et al. also 
showed a significant increase in serum albumin in acute pancreatitis 
patients supplemented with parenteral glutamine. This is particularly 
important in Indian population who are prone to malnutrition and 
hypoproteinemia, an important predictor of morbidity and mortality 
in hospitalized patients [20]. There was no significant change in both 
intergroup and intragroup comparison in the blood glucose levels in 
Table 1: Comparison of baseline characteristics among different groups (n=22)
Variables Group 1 (n‑22) Group 2 (n‑22) Group 3 (n‑22) p
Age (y) 60.5±5.4 62.8±2.8 58.6±6.4 p>0.05
Gender (M/F) 12/10 13/9 15/7 p>0.05
BMI (kg/m2) 28.1±1.4 25.9±2.1 26.7±1.9 p>0.05
Number of patients on mechanical ventilation 4 4 3 p>0.05
Serum lactate (mmol/l) 3.5±1.1 3.9±1.3 3.4±0.9 p>0.05
Serum bilirubin (mg/dl) 1.6±0.6 1.8±0.4 1.4±0.7 p>0.05
Serum creatinine (mg/dl) 0.8±0.2 0.9±0.3 0.8±0.1 p>0.05
Blood glucose (mg/dl) 140±6 138±9 142±7 p>0.05
APACHE II score 14.45±4.22 13.68±2.8 14.2±4.16 p>0.05
SOFA score 4.9±0.8 5.1±0.6 5.4±0.9 p>0.05
BMI: Body mass index
Table 2: Comparison of parameters in Group 1
Variables Day 1 Day 4 Day 7 p
Total leukocyte count (thousand/cm2) 9.23±1.62 9.94±1.34 8.44±0.95 0.061
Lymphocyte count (thousand/cm2) 2.82±0.42 2.58±0.64 2.60±0.55 0.195
Protein (g/dl) 5.77±0.15 6.40±0.19 5.18±0.22 0.580
Albumin (g/dl) 2.94±0.06 2.63±0.09 2.55±0.08 0.385
Serum lactate (mmol/l) 2.84±0.08 3.25±0.29 2.67±0.11 0.727
SOFA score 6.00±0.12 4.00±0.31 3.50±0.18 <0.001
Table 3: Comparison of parameters in Group 2
Variables Day 1 Day 4 Day 7 p
TLC (thousand/cm2) 12.61±1.34 11.18±1.10 10.10±1.85 0.834
Lymphocyte count (thousand/cm2) 2.09±0.34 1.97±0.25 2.42±0.52 0.142
Protein (g/dl) 5.56±0.64 5.55±0.75 5.64±0.82 0.422
Albumin (g/dl) 2.44±0.04 2.91±0.06 3.52±0.09 0.075
Serum lactate (mmol/l) 2.98±0.01 2.92±0.04 2.90±0.03 0.280
SOFA score 6.00±0.15 5.00±0.19 2.50±0.12 <0.001
TLC: Total leukocyte count
Table 4: Comparison of parameters in Group 3
Variables Day 1 Day 4 Day 7 p
TLC (thousand/cm2) 14.97±1.96 12.84±1.74 10.49±1.42 0.035
Lymphocyte count (thousand/cm2) 1.76±0.5 1.83±0.43 2.3±0.18 0.031
Protein (g/dl) 6.10±0.89 6.00±0.41 6.17±0.65 0.045
Albumin (g/dl) 2.97±0.02 3.34±0.06 3.43±0.09 0.042
Serum lactate (mmol/l) 3.05±0.01 3.07±0.03 2.97±0.01 0.04
SOFA score 6.00±0.12 4.50±0.16 2.00±0.24 <0.001
TLC: Total leukocyte count
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our study. There was no significant different in the mortality among the 
three group. The number of deaths in Group 3 was lesser but was of 
not statistically significant. The LOS in ICU and duration of mechanical 
ventilation as predictors of morbidity was not statistically different 
among the three groups.
This was consistent with the results of the previous studies who studied 
the effect of glutamine as a nonsignificant predictor of morbidity 
and mortality [21-26]. A meta-analysis by Oldani et al. analyzing 30 
randomized controlled trials (RCTs) with a total of 3696 patients, 1852 
receiving glutamine in elective surgical and critically ill patients and 
showed a moderate reduction in mortality in the parenteral group [27]. 
Bollhalder et al. also included 11 RCTs and concluded that glutamine 
given at a dose >0.2 g/kg/day for at least 9 days was associated with 
a decreased mortality rate, reduced hospital stay, and reduction in 
infectious complications [28]. Meta-analysis by Chen et al. showed no 
benefit of glutamine on mortality or LOS although there was a reduction 
in infections in the infections in the glutamine-supplemented group [29]. 
Tao et al. showed a low-quality evidence that glutamine reduces the LOS 
and showed no effect on mortality [30]. Meta-analysis by Kang et al. to 
assess the effect of glutamine in surgical patients with GI tumors showed 
improved immune function, reduce infections and shortened the length of 
ICU stay. Enteral glutamine supplementation does not confer significant 
benefits in the treatment of critically ill patients [31]. In burned patients, 
there may be a benefit reducing mortality and infectious morbidity, 
but data are scarce, and broader studies are warranted to confirm 
this effect [32]. John and Aanandhi, in their study, have concluded that 
the supplementation of enteral glutamine in post-operative patients 
decreases the incidence of post-surgical infection, shortening of hospital 
stay, and reduction in the overall hospital costs which were similar to our 
study [33]. Oktavia et al. in a review of many studies in critically ill adults 
suggested that glutamine-supplemented amino acid solutions may reduce 
mortality, improve nitrogen balance, and reduce the incidence of clinical 
infection [34]. Available data on glutamine-supplemented via parenteral 
nutrition cannot be compared to enteral nutrition supplemented and 
therefore cannot be used as the basis for recommendation of enteral 
glutamine administration. Despite this apparent paradigm change, there 
is sufficient evidence in the literature on the benefits of glutamine that 
impel us to continue research by putting forth new questions.
CONCLUSION
Our findings are in contrast to recently published Redox study and 
Signet study. It is not easy to obtain a clear answer to the above-quoted 
question, as the critically ill population is a heterogeneous one. Studies 
often mix patients with different pathologies and prognoses, as well 
as include distinct routes of administration and the use of different 
doses than those recommended by the guidelines, thus giving mixed 
results, especially when compared to a meta-analysis. The effect of 
parenteral glutamine supplementation on mortality differed with 
patient population, mode of nutrition, and glutamine dosages. There 
are differences in subpopulations of ICU patients with a beneficial 
improvement in the surgical population versus medical or mixed ICU 
population. Future research must explorer the mechanism by which 
a glutamine deficiency could be harmful for some patients and bow 
patients and how to be supplemented both dose and route.
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